A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
← catalyst calendarNCT06581406 · readout ≤ 1,261 d
Sponsored by Replimune, Inc. (industry) · REPL — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
280estimated
Sites
33
Countries
Australia, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-17 | actual | When the study began enrolling |
| Primary completion | Jan 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Uveal Melanoma
Interventions
- Biological: RP2
- Biological: Ipilimumab — also filed as Yervoy
- Biological: Nivolumab — also filed as Opdivo
Primary outcomes
what the primary-completion date above is the date OFOverall Survival (OS)
measured From Day 1 up to 3 years after last dose.
Progression Free Survival (PFS)
measured From Day 1 up to 3 years after last dose.
Permalink · REPL's whole pipeline · Catalyst calendar · Every registered study · What changed